Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Vaccines

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 164 articles: HTML format Text format

Single Articles

October 2018
1. PATEL A, Reuschel EL, Kraynyak KA, Racine T, et al
   Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines.
   J Infect Dis. 2018 Oct 10. pii: 5123708. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
2. KUDO R, Yamaguchi M, Sekine M, Adachi S, et al
   Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
   J Infect Dis. 2018 Oct 9. pii: 5115492. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   September 2018
3. PRAHARAJ I, Parker EPK, Giri S, Allen DJ, et al
   Influence of non-polio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from south India.
   J Infect Dis. 2018 Sep 24. pii: 5106276. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
4. RAMANI S, Harris V
   Going Viral! Unraveling the Impact of Non-polio Enteroviruses on Oral Vaccine Responses.
   J Infect Dis. 2018 Sep 24. pii: 5106282. doi: 10.1093.
   PubMed     Text format    
   
   
   
5. PATEL NP, Vukmanovic-Stejic M, Suarez-Farinas M, Chambers ES, et al
   Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge.
   J Infect Dis. 2018;218.
   PubMed     Text format     Abstract available
   
   
   
6. HARPAZ R, van Hoek AJ
   Point-Counterpoint: The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence.
   J Infect Dis. 2018;218.
   PubMed     Text format     Abstract available
   
   
   
7. GILBERT PB, Luedtke AR
   Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials.
   J Infect Dis. 2018;218.
   PubMed     Text format     Abstract available
   
   
   
8. WEINBERG A, Kroehl ME, Johnson MJ, Hammes A, et al
   Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
   J Infect Dis. 2018;218.
   PubMed     Text format     Abstract available
   
   
   
9. TSENG HF, Sy LS
   Use of Real-world Evidence to Evaluate the Effectiveness of Herpes Zoster Vaccine.
   J Infect Dis. 2018;218.
   PubMed     Text format     Abstract available
   
   
   
10. CUNNINGHAM AL, Levin MJ
    Herpes Zoster Vaccines.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available
    
    
    
11. BREUER J
    Molecular Genetic Insights Into Varicella Zoster Virus (VZV), the vOka Vaccine Strain, and the Pathogenesis of Latency and Reactivation.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available
    
    
    
12. PARKER EPK, Whitfield H, Baskar C, Giri S, et al
    FUT2 secretor status is not associated with oral poliovirus vaccine immunogenicity in south Indian infants.
    J Infect Dis. 2018 Sep 19. pii: 5102389. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
13. ARTEMCHUK H, Eriksson T, Poljak M, Surcel HM, et al
    Long-Term Antibody Response to Human Papillomavirus Vaccines: up to 12 Years Follow-Up in the Finnish Maternity Cohort.
    J Infect Dis. 2018 Sep 18. pii: 5099444. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
14. SCHALTZ-BUCHHOLZER F, Biering-Sorensen S, Lund N, Monteiro I, et al
    Early Bacille Calmette-Guerin vaccination, hospitalizations and hospital deaths: Analysis of a secondary outcome in three randomized trials from Guinea-Bissau.
    J Infect Dis. 2018 Sep 18. pii: 5099442. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. CIGLENECKI I, Azman AS, Jamet C, Serafini M, et al
    Progress and Challenges in Using Oral Cholera Vaccines to Control Outbreaks: The Medecins Sans Frontieres Experience.
    J Infect Dis. 2018 Sep 14. pii: 5098246. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
16. ATMAR RL, Cramer JP, Baehner F, Han C, et al
    An exploratory study of the salivary IgA responses to one dose of a Norovirus VLP candidate vaccine in healthy adults.
    J Infect Dis. 2018 Sep 10. pii: 5094041. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
17. MARSHALL HS, Clarke M, Heath C, Quinn H, et al
    Severe and complicated varicella and associated genotypes 10 years after introduction of a one dose varicella vaccine program.
    J Infect Dis. 2018 Sep 3. pii: 5089719. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
18. HARRIS JB
    Cholera: Immunity and Prospects in Vaccine Development.
    J Infect Dis. 2018 Sep 1. pii: 5089248. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    August 2018
19. WEINBERG A, Popmihajlov Z, Schmader KE, Johnson MJ, et al
    Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine.
    J Infect Dis. 2018 Aug 28. pii: 5084879. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
20. LI Z, Chang P, Xu J, Tan C, et al
    A Streptococcus suis live vaccine suppresses streptococcal toxic shock-like syndrome and provides sequence type independent protectionTITLE.
    J Infect Dis. 2018 Aug 27. pii: 5081797. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
21. CAGIGI A, Ploquin A, Niezold T, Zhou Y, et al
    Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction.
    J Infect Dis. 2018 Aug 22. pii: 5078072. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
22. CHANOUZAS D, Sagmeister M, Faustini S, Nightingale P, et al
    Subclinical reactivation of cytomegalovirus drives CD4+CD28null T-cell expansion and impaired immune response to pneumococcal vaccination in ANCA-associated vasculitis.
    J Infect Dis. 2018 Aug 9. pii: 5068409. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
23. LIANG Y, Che Y, Yang B, Zhan F, et al
    Immunogenicity and safety of an F-genotype attenuated mumps vaccine in healthy 8- to 24-month-old children.
    J Infect Dis. 2018 Aug 1. pii: 5063175. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
24. LAZCANO-PONCE E, Torres-Ibarra L, Cruz-Valdez A, Salmeron J, et al
    Persistence of immunity when using different HPV vaccination schedules and booster dose effects at 5 years post-primary vaccination.
    J Infect Dis. 2018 Aug 1. pii: 5063117. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    July 2018
25. SUSCHAK JJ, Bagley K, Shoemaker CJ, Six C, et al
    The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice.
    J Infect Dis. 2018 Jul 19. pii: 5056373. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
26. FEIRING B, Laake I, Christiansen IK, Hansen M, et al
    Substantial decline in prevalence of vaccine-type and non-vaccine type HPV in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway.
    J Infect Dis. 2018 Jul 16. pii: 5054086. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
27. POPPER SJ, Strouts FR, Lindow JC, Cheng HK, et al
    Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers.
    J Infect Dis. 2018 Jul 14. pii: 5053882. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
28. CAGIGI A, Misasi J, Ploquin A, Stanley DA, et al
    Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures.
    J Infect Dis. 2018 Jul 12. pii: 5052389. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
29. VAN WAGONER N, Fife K, Leone PA, Bernstein DI, et al
    Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital HSV-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-controlled Trial.
    J Infect Dis. 2018 Jul 6. pii: 5049813. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
30. ANGUIANO-ZARATE SS, Matchett WE, Nehete P, Sastry KJ, et al
    A Replicating Single-cycle Adenovirus Vaccine against Ebola Virus.
    J Infect Dis. 2018 Jul 6. pii: 5049708. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
31. HOLBROOK MR
    Will a single-cycle Adenovirus vaccine be effective against Ebola virus?
    J Infect Dis. 2018 Jul 6. pii: 5049709. doi: 10.1093.
    PubMed     Text format    
    
    
    
32. YOUSAFZAI MT
    Role of fractional dose intradermal inactivated poliovirus vaccine in halting polio transmission: finding the missing piece for global polio eradication.
    J Infect Dis. 2018 Jul 5. pii: 5049362. doi: 10.1093.
    PubMed     Text format    
    
    
    
33. GAMAGE D, Mach O, Palihawadana P, Zhang Y, et al
    Boosting of mucosal immunity after fractional-dose inactivated poliovirus vaccine.
    J Infect Dis. 2018 Jul 5. pii: 5049361. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    June 2018
34. WARFIELD KL, Howell KA, Vu H, Geisbert J, et al
    Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.
    J Infect Dis. 2018 Jun 25. pii: 5043486. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
35. FUENTES S, Ravichandran S, Khurana S
    Antibody Repertoire of Human Polyclonal Antibodies Against Ebola Virus Glycoprotein Generated After Deoxyribonucleic Acid and Protein Vaccination of Transchromosomal Bovines.
    J Infect Dis. 2018 Jun 25. pii: 5043463. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
36. LIU F, Tzeng WP, Horner L, Kamal RP, et al
    Both Immune Priming and Egg-adaptation in the Vaccine Influence Antibody Responses to Circulating A(H1N1)pdm09 Viruses Following Influenza Vaccination in Adults.
    J Infect Dis. 2018 Jun 21. pii: 5042019. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
37. SOUCY AM, Hurteau GJ, Metzger DW
    Live vaccination generates both disease tolerance and host resistance during chronic pulmonary infection with highly virulent F. tularensis SchuS4.
    J Infect Dis. 2018 Jun 20. pii: 5040507. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
38. MESHER D, Panwar K, Thomas SL, Edmundson C, et al
    The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
    J Infect Dis. 2018 Jun 18. pii: 5025126. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
39. LIU Y, Ye L, Lin F, Gomaa Y, et al
    Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.
    J Infect Dis. 2018 Jun 8. pii: 5034941. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    May 2018
40. SWANSTROM JA, Henein S, Plante JA, Yount BL, et al
    Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
    J Infect Dis. 2018;217:1932-1941.
    PubMed     Text format     Abstract available
    
    
    
41. KAINULAINEN MH, Spengler JR, Welch SR, Coleman-McCray JD, et al
    Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    J Infect Dis. 2018;217:1957-1966.
    PubMed     Text format     Abstract available
    
    
    
42. PERCIANI CT, Sekhon M, Hundal S, Farah B, et al
    Live-attenuated Zoster Vaccine Boosts VZV-specific Humoral Responses Systemically and at the Cervico-vaginal Mucosa of Kenyan VZV-seropositive Women.
    J Infect Dis. 2018 May 25. pii: 5003463. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
43. CHAKRABORTY S, Randall A, Vickers TJ, Molina D, et al
    Human experimental challenge with enterotoxigenic Escherichia coli elicits immune responses to canonical and novel antigens relevant to vaccine development.
    J Infect Dis. 2018 May 24. pii: 5003007. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
44. PAMNANI SJ, Sudenga SL, Rollison DE, Ingles DJ, et al
    Recurrence of Genital Infections with Nine HPV Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) among Men in the HPV Infection in Men (HIM) Study.
    J Infect Dis. 2018 May 24. pii: 5002064. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
45. BERNSTEIN DI
    Rotavirus Vaccines: Mind Your Ps and Gs.
    J Infect Dis. 2018 May 22. pii: 5001445. doi: 10.1093.
    PubMed     Text format    
    
    
    
46. ROCZO-FARKAS S, Kirkwood CD, Cowley D, Barnes GL, et al
    The Impact of Rotavirus Vaccines on Genotype Diversity: A Comprehensive Analysis of 2 Decades of Australian Surveillance Data.
    J Infect Dis. 2018 May 22. pii: 5001444. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
47. KABINEH AK, Carr W, Motevalli M, Legardy-Williams J, et al
    Operationalizing International Regulatory Standards in a Limited-Resource Setting During an Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Experience.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
48. CARTER RJ, Senesi RGB, Dawson P, Gassama I, et al
    Participant Retention in a Randomized Clinical Trial in an Outbreak Setting: Lessons From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
49. CONTEH MA, Goldstein ST, Wurie HR, Gidudu J, et al
    Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
50. JARRETT OD, Seward JF, Fombah AE, Lindblad R, et al
    Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
51. SAMAI M, Seward JF, Goldstein ST, Mahon BE, et al
    The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVG-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
52. SCHUCHAT A, Seward JF, Goldstein ST, Mahon BE, et al
    Comment: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format    
    
    
    
53. CARTER RJ, Idriss A, Widdowson MA, Samai M, et al
    Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
54. FOMBAH AE, Goldstein ST, Jarrett OD, Jalloh MI, et al
    Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
55. EDEM-HOTAH J, McDonald W, Abu PM, Luman ET, et al
    Utilizing Nurses to Staff an Ebola Vaccine Clinical Trial in Sierra Leone during the Ebola Outbreak.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
56. JUSU MO, Glauser G, Seward JF, Bawoh M, et al
    Rapid Establishment of a Cold Chain Capacity of -60 degrees C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available
    
    
    
57. GARLAND SM, Pitisuttithum P, Ngan HYS, Cho CH, et al
    Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    J Infect Dis. 2018 May 15. pii: 4996119. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
58. FARMAKI PF, Chini MC, Mangafas NM, Tzanoudaki MT, et al
    Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    J Infect Dis. 2018 May 2. pii: 4990938. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    April 2018
59. CARROLL TD, Jegaskanda S, Matzinger SR, Fritts L, et al
    A lipid/DNA adjuvant-inactivated influenza virus vaccine protects rhesus macaques from uncontrolled virus replication after heterosubtypic influenza A virus challenge.
    J Infect Dis. 2018 Apr 26. pii: 4986227. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
60. JOYCE JC, Carroll TD, Collins ML, Chen MH, et al
    A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.
    J Infect Dis. 2018 Apr 26. pii: 4986788. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
61. AMLABU E, Mensah-Brown H, Nyarko PB, Akuh OA, et al
    Functional Characterization of Plasmodium falciparum Surface Related Antigen (PfSRA) as a Potential Blood-Stage Vaccine Target.
    J Infect Dis. 2018 Apr 18. pii: 4975396. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
62. DE VRIES RD, Altenburg AF, Nieuwkoop NJ, de Bruin E, et al
    Induction of Cross-Clade Antibody and T-Cell Responses by an MVA-Based Influenza H5N1 Vaccine in a Randomized Phase I/IIa Clinical Trial.
    J Infect Dis. 2018 Apr 18. pii: 4975691. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
63. LIN KY, Hsieh SM, Sheng WH, Lo YC, et al
    Comparable serologic responses to 2 different combinations of inactivated HAV vaccines in HIV-positive patients during the acute hepatitis A outbreak in Taiwan.
    J Infect Dis. 2018 Apr 16. pii: 4972613. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
64. BADEN LR, Walsh SR, Seaman MS, Cohen YZ, et al
    First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    J Infect Dis. 2018 Apr 13. pii: 4969772. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
65. HAIDARA FC, Tapia MD, Sow SO, Doumbia M, et al
    Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants.
    J Infect Dis. 2018 Apr 12. pii: 4969416. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
66. ZIMMERMANN P, Finn A, Curtis N
    Does BCG Vaccination Protect Against Non-Tuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis.
    J Infect Dis. 2018 Apr 7. pii: 4964710. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    March 2018
67. LANGLEY JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, et al
    A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.
    J Infect Dis. 2018 Mar 30. pii: 4956800. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
68. MANNING JE, Morens DM, Kamhawi S, Valenzuela JG, et al
    Mosquito saliva: the hope for a universal arbovirus vaccine?
    J Infect Dis. 2018 Mar 29. pii: 4956143. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
69. GUO Q, Chan JF, Poon VK, Wu S, et al
    Immunization with a Novel Human type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models.
    J Infect Dis. 2018 Mar 29. pii: 4956202. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
70. FENG G, Boyle MJ, Cross N, Chan JA, et al
    Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains.
    J Infect Dis. 2018 Mar 23. pii: 4952401. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
71. PATEL EU, Grabowski MK, Eisenberg AL, Packman ZR, et al
    Increases in Human Papillomavirus Vaccination Among Adolescent and Young Adult Males in the United States, 2011-2016.
    J Infect Dis. 2018 Mar 23. pii: 4951824. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
72. ANGRISANO F, Blagborough AM
    Understanding human-derived antibodies generated by polymorphic malaria vaccine against merozoite surface protein 2.
    J Infect Dis. 2018 Mar 23. pii: 4952403. doi: 10.1093.
    PubMed     Text format    
    
    
    
73. SCHLEISS MR
    Searching for a Serological Correlate of Protection for a CMV Vaccine.
    J Infect Dis. 2018 Mar 8. pii: 4924674. doi: 10.1093.
    PubMed     Text format    
    
    
    
74. BARANIAK I, Kropff B, McLean GR, Pichon S, et al
    Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine with MF59: Anti-AD2 Levels Correlate with Protection from Viremia.
    J Infect Dis. 2018 Mar 8. pii: 4924673. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
75. ROGAWSKI ET, Platts-Mills JA, Colgate ER, Haque R, et al
    Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study.
    J Infect Dis. 2018;217:861-868.
    PubMed     Text format     Abstract available
    
    
    
76. BUCHHOLZ UJ, Cunningham CK, Muresan P, Gnanashanmugam D, et al
    Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
    J Infect Dis. 2018 Mar 2. pii: 4917539. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
77. POLACK FP
    Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus.
    J Infect Dis. 2018 Mar 2. pii: 4917537. doi: 10.1093.
    PubMed     Text format    
    
    
    
78. MCFARLAND EJ, Karron RA, Muresan P, Cunningham CK, et al
    Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.
    J Infect Dis. 2018 Mar 2. pii: 4917538. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    February 2018
79. ERBELDING EJ, Post D, Stemmy E, Roberts PC, et al
    A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.
    J Infect Dis. 2018 Feb 28. pii: 4904047. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
80. CUNNINGHAM AL, Heineman TC, Lal H, Godeaux O, et al
    Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged >/=50 Years.
    J Infect Dis. 2018 Feb 26. pii: 4911103. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
81. YOUNG-XU Y, Van Aalst R, Mahmud SM, Rothman KJ, et al
    Relative Vaccine Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines among Veterans Health Administration Patients.
    J Infect Dis. 2018 Feb 14. pii: 4858294. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
82. KOJIC EM, Conley L, Bush T, Cu-Uvin S, et al
    Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types covered by Current HPV Vaccines among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (The SUN Study
    J Infect Dis. 2018 Feb 14. pii: 4857222. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
83. LO NC, Gupta R, Stanaway JD, Garrett DO, et al
    Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    J Infect Dis. 2018 Feb 12. pii: 4851280. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
84. ZENKLUSEN I, Jongo S, Abdulla S, Ramadhani K, et al
    Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies.
    J Infect Dis. 2018 Feb 8. pii: 4845622. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
85. MACHALEK DA, Garland SM, Brotherton JML, Bateson D, et al
    Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination.
    J Infect Dis. 2018 Feb 7. pii: 4841780. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
86. FREYNE B, Donath S, Germano S, Gardiner K, et al
    Neonatal BCG vaccination influences cytokine responses to Toll-like receptor ligands and heterologous antigens.
    J Infect Dis. 2018 Feb 3. pii: 4837044. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
87. DONKEN R, King AJ, Bogaards JA, Woestenberg PJ, et al
    High effectiveness of the bivalent HPV vaccine up to six years post-vaccination against incident and persistent HPV infections in young Dutch females.
    J Infect Dis. 2018 Feb 2. pii: 4835373. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
88. LEVIN MJ, Cai GY, Lee KS, Rouphael NG, et al
    Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.
    J Infect Dis. 2018 Feb 2. pii: 4835758. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
89. POLLOCK KGJ
    Sustained cross-protection of the bivalent HPV vaccine.
    J Infect Dis. 2018 Feb 2. pii: 4835375. doi: 10.1093.
    PubMed     Text format    
    
    
    
90. BERAN J, Lickliter JD, Schwarz TF, Johnson C, et al
    Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in non-pregnant women: results from two phase II trials.
    J Infect Dis. 2018 Feb 1. pii: 4833521. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
91. SHANG L, Smith AJ, Duan L, Perkey KE, et al
    Vaccine-associated maintenance of epithelial integrity correlated with protection against virus entry.
    J Infect Dis. 2018 Feb 1. pii: 4833184. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    January 2018
92. LEE B, Dickson DM, deCamp AC, Colgate ER, et al
    Histoblood Group Antigen Phenotype Determines Susceptibility to Genotype-specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy.
    J Infect Dis. 2018 Jan 30. pii: 4829672. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
93. MALHOTRA I, LaBeaud AD, Morris N, McKibben M, et al
    Cord Blood Anti-Parasite IL-10 as Risk Marker for Compromised Vaccine Immunogenicity in Early Childhood.
    J Infect Dis. 2018 Jan 30. pii: 4829506. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
94. JUNG J, Ko SJ, Oh HS, Moon SM, et al
    Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome.
    J Infect Dis. 2018 Jan 24. pii: 4823438. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
95. CHENG AC, Subbarao K
    Epidemiological Data on the Effectiveness of Influenza Vaccine-Another Piece of the Puzzle.
    J Infect Dis. 2018 Jan 18. pii: 4816917. doi: 10.1093.
    PubMed     Text format    
    
    
    
96. FLANNERY B, Smith C, Garten RJ, Levine MZ, et al
    Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.
    J Infect Dis. 2018 Jan 18. pii: 4816916. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
97. CHIU SS, Kwan MYW, Feng S, Wong JSC, et al
    Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17.
    J Infect Dis. 2018 Jan 16. pii: 4810661. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
98. KAPIL P, Papin JF, Wolf RF, Zimmerman LI, et al
    Maternal Vaccination with a Mono-component Pertussis Toxoid Vaccine is Sufficient to Protect Infants in a Baboon Model of Whooping Cough.
    J Infect Dis. 2018 Jan 15. pii: 4808590. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
99. CAPEDING MR, Alberto ER, Bouckenooghe A, Laot TM, et al
    Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
    J Infect Dis. 2018 Jan 9. pii: 4794746. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
100. PRINGLE KD, Burke RM, Steiner CA, Parashar UD, et al
     Trends in Rate of Seizure-Associated Hospitalizations Among Children <5 Years Old Before and After Rotavirus Vaccine Introduction in the United Sates, 2000-2013.
     J Infect Dis. 2018 Jan 9. pii: 4796788. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
101. FONG Y, Shen X, Ashley VC, Deal A, et al
     Vaccine-induced antibody responses modify the association between T-cell immune responses and HIV-1 infection risk in HVTN 505.
     J Infect Dis. 2018 Jan 8. pii: 4792964. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
102. BRICKLEY EB, Strauch CB, Wieland-Alter WF, Connor RI, et al
     Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
     J Infect Dis. 2018 Jan 3. pii: 4788281. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
103. SUTTER RW
     Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine.
     J Infect Dis. 2018 Jan 3. pii: 4788256. doi: 10.1093.
     PubMed     Text format    
     
     
     
104. GIRI S, Kumar N, Dhanapal P, Venkatesan J, et al
     The quantity of vaccine poliovirus shedding determines the titer of the serum neutralizing antibody response in Indian children vaccinated with oral vaccine.
     J Infect Dis. 2018 Jan 2. pii: 4782493. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     December 2017
105. RAMILO O, Rodriguez-Fernandez R, Mejias A
     One Step Forward in the Road Toward a Universal Influenza Vaccine.
     J Infect Dis. 2017;217:1-2.
     PubMed     Text format    
     
     
     
106. MAJUMDAR M, Klapsa D, Wilton T, Akello J, et al
     Isolation of vaccine-like poliovirus strains in sewage samples from the UK.
     J Infect Dis. 2017 Dec 22. pii: 4772162. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
107. MEYER M, Huang E, Yuzhakov O, Ramanathan P, et al
     Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.
     J Infect Dis. 2017 Dec 21. pii: 4770157. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
108. DURBIN AP, Whitehead SS
     Zika Vaccines: Role for Controlled Human Infection.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
109. MORABITO KM, Graham BS
     Zika Virus Vaccine Development.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
110. GRUBER MF, Farizo KM, Pratt RD, Fink DL, et al
     Clinical Development Strategies and Considerations for Zika Vaccine Licensure.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
111. VOIGT EA, Haralambieva IH, Larrabee BL, Kennedy RB, et al
     Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination.
     J Infect Dis. 2017 Dec 14. pii: 4743250. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
112. MADARAS-KELLY K, Remington R, Hruza H, Xu D, et al
     The Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines in Preventing Post-Influenza Deaths.
     J Infect Dis. 2017 Dec 9. pii: 4718125. doi: 10.1093.
     PubMed     Text format    
     
     
     
113. YOUNG B, Sadarangani S, Jiang L, Wilder-Smith A, et al
     The Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis and Meta-regression of Test-Negative Design Case-control Studies.
     J Infect Dis. 2017 Dec 6. pii: 4694421. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
114. OHFUJI S, Deguchi M, Tachibana D, Koyama M, et al
     Protective effect of maternal influenza vaccination on influenza in their infants: a prospective cohort study.
     J Infect Dis. 2017 Dec 5. pii: 4693945. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
115. BURN C, Ramsey N, Garforth SJ, Almo S, et al
     An HSV-2 single-cycle candidate vaccine deleted in glycoprotein D, DeltagD-2, protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2.
     J Infect Dis. 2017 Dec 5. pii: 4693944. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
116. LIU WC, Lin CS, Yeh CC, Wu HY, et al
     Effect of Influenza Vaccination Against Postoperative Pneumonia and Mortality for Geriatric Patients Receiving Major Surgery: A Nationwide Matched Study.
     J Infect Dis. 2017 Dec 5. pii: 4690590. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
117. HAGAN JE, Takashima Y, Sarankhuu A, Dashpagma O, et al
     Risk Factors for Measles Virus Infection Among Adults During a Large Outbreak in Postelimination Era in Mongolia, 2015.
     J Infect Dis. 2017;216:1187-1195.
     PubMed     Text format     Abstract available
     
     
     November 2017
118. MOODIE Z, Juraska M, Huang Y, Zhuang Y, et al
     Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
     J Infect Dis. 2017 Nov 29. pii: 4675250. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
119. SCHERER EM, Smith RA, Carter JJ, Wipf GC, et al
     Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine.
     J Infect Dis. 2017 Nov 24. pii: 4657105. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
120. HIRAMATSU H, Suzuki R, Nagatani A, Boda H, et al
     Rotavirus vaccination can be performed without viral dissemination in the Neonatal Intensive Care Unit.
     J Infect Dis. 2017 Nov 20. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
121. DREW DR, Sanders PR, Weiss G, Gilson PR, et al
     Functional conservation of the AMA1 host-cell invasion ligand between P. falciparum and P. vivax: a novel platform to accelerate vaccine and drug development.
     J Infect Dis. 2017 Nov 20. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
122. CHEN HL, Wen WH, Chang MH
     Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
123. OLDFIELD NJ, Green LR, Parkhill J, Bayliss CD, et al
     Limited impact of adolescent meningococcal ACWY vaccination on group W carriage in university students.
     J Infect Dis. 2017 Nov 15. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
124. LEROUX-ROELS G, Cramer JP, Mendelman PM, Sherwood J, et al
     Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial.
     J Infect Dis. 2017 Nov 13. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
125. WOESTENBERG PJ, King AJ, van Benthem BHB, Donken R, et al
     Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors.
     J Infect Dis. 2017 Nov 11. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
126. NOVAKOVIC D, Cheng ATL, Zurynski Y, Booy R, et al
     A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program.
     J Infect Dis. 2017 Nov 9. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
127. DONOVAN B, Callander D
     Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue.
     J Infect Dis. 2017 Nov 9. doi: 10.1093.
     PubMed     Text format    
     
     
     
128. SALEEM AF, Mach O, Yousafzai MT, Khan A, et al
     Immunogenicity of Different Routine Poliovirus Vaccination Schedules: a Randomized Controlled Trial, Karachi, Pakistan.
     J Infect Dis. 2017 Nov 6. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
129. VANDERVEN HA, Jegaskanda S, Wines BD, Hogarth PM, et al
     Antibody-dependent cellular cytotoxicity (ADCC) responses to seasonal influenza vaccination in older adults.
     J Infect Dis. 2017 Nov 2. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     October 2017
130. SICRE DE FONTBRUNE F, Arnaud C, Cheminant M, Boulay A, et al
     Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy.
     J Infect Dis. 2017 Oct 26. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
131. SKOWRONSKI DM, Chambers C, De Serres G
     Selection bias in the assessment of frailty and its role in influenza vaccine effectiveness evaluation among elderly adults.
     J Infect Dis. 2017 Oct 13. doi: 10.1093.
     PubMed     Text format    
     
     
     
132. SKOWRONSKI DM, Chambers C, Sabaiduc S, De Serres G, et al
     Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-16 season in Canada.
     J Infect Dis. 2017 Oct 4. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     September 2017
133. BELONGIA E
     Beyond Antigenic Match: Moving Toward Greater Understanding of Influenza Vaccine Effectiveness.
     J Infect Dis. 2017 Sep 27. doi: 10.1093.
     PubMed     Text format    
     
     
     
134. OXMAN MN, Harbecke R, Koelle DM
     Clinical Usage of the Candidate Adjuvanted HZ/su Zoster Vaccine: re-vaccination of recipients of live attenuated zoster vaccine and co-administration with a seasonal influenza vaccine.
     J Infect Dis. 2017 Sep 26. doi: 10.1093.
     PubMed     Text format    
     
     
     
135. SCHWARZ TF, Aggarwal N, Moeckesch B, Schenkenberger I, et al
     Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older.
     J Infect Dis. 2017 Sep 26. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
136. GRUPPING K, Campora L, Douha M, Heineman TC, et al
     Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine.
     J Infect Dis. 2017 Sep 26. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
137. FALLOON J, Yu J, Esser MT, Villafana T, et al
     An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
     J Infect Dis. 2017 Sep 23. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
138. NICHOLSON E, Piedra PA
     Local Versus Global Enterovirus (EV) Surveillance: A Discussion For The Need for Active Surveillance To Guide EV A71 Vaccines.
     J Infect Dis. 2017 Sep 23. doi: 10.1093.
     PubMed     Text format    
     
     
     
139. LANGLEY JM
     Vaccine Prevention of Respiratory Syncytial Virus in Older Adults: The Work Continues.
     J Infect Dis. 2017 Sep 23. doi: 10.1093.
     PubMed     Text format    
     
     
     
140. LEVINE MZ, Holiday C, Liu F, Jefferson S, et al
     Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
141. JONES EN, Amoah S, Cao W, Sambhara S, et al
     An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
142. PODDIGHE D
     2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine.
     J Infect Dis. 2017;216:782-783.
     PubMed     Text format    
     
     
     
143. TAI CS, Wu JF, Chen HL, Ni YH, et al
     The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
     J Infect Dis. 2017;216:662-669.
     PubMed     Text format     Abstract available
     
     
     
144. TORRESI J, Richmond PC, Heron LG, Qiao M, et al
     Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
     J Infect Dis. 2017 Sep 14. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
145. DROLET M, Laprise JF, Brotherton JML, Donovan B, et al
     The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation.
     J Infect Dis. 2017 Sep 12. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
146. DUNKLE LM, Izikson R, Patriarca PA, Goldenthal KL, et al
     Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
     J Infect Dis. 2017 Sep 9. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
147. AKE JA, Schuetz A, Pegu P, Wieczorek L, et al
     Safety and Immunogenicity of PENNVAX(R)-G DNA Prime Administered by Biojector(R) 2000 or CELLECTRA(R) Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.
     J Infect Dis. 2017 Sep 2. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
148. NING T, Wolfe A, Nie J, Huang W, et al
     Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.
     J Infect Dis. 2017 Sep 2. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
149. OLIVER SE, Unger ER, Lewis R, McDaniel D, et al
     Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
     J Infect Dis. 2017;216:594-603.
     PubMed     Text format     Abstract available
     
     
     August 2017
150. MCNAMARA LA, Thomas JD, MacNeil J, Chang HY, et al
     Meningococcal Carriage Following a University Serogroup B Meningococcal Disease Outbreak and Vaccination Campaign with MenB-4C and MenB-FHbp - Oregon, 2015-2016.
     J Infect Dis. 2017 Aug 26. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
151. LEHTINEN T, Soderlund-Strand A, Petaja T, Eriksson T, et al
     Human papillomavirus (HPV) prevalence in adolescent males four years post HPV16/18 vaccination.
     J Infect Dis. 2017 Aug 24. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
152. MODROF J, Tille B, Farcet MR, McVey J, et al
     Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins:is an Increase by Re-Vaccination of Plasma Donors possible?
     J Infect Dis. 2017 Aug 18. doi: 10.1093.
     PubMed     Text format     Abstract available
     
     
     
153. NEUZIL KM, Chen WH
     Influenza Vaccines for Older Persons: Progress and Pitfalls.
     J Infect Dis. 2017;216:397-398.
     PubMed     Text format    
     
     
     
154. ANDREW MK, Shinde V, Ye L, Hatchette T, et al
     The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People.
     J Infect Dis. 2017;216:405-414.
     PubMed     Text format     Abstract available
     
     
     
155. VAN BEEK J, Veenhoven RH, Bruin JP, van Boxtel RAJ, et al
     Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections.
     J Infect Dis. 2017;216:415-424.
     PubMed     Text format     Abstract available
     
     
     
156. MCELHANEY JE, McNeil SA
     Test-Negative Design: The Importance of Laboratory-Confirmed Illness in Estimating the Effectiveness of Influenza Vaccine in Older Adults.
     J Infect Dis. 2017;216:399-401.
     PubMed     Text format    
     
     
     
157. LIBRATY DH
     Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
     J Infect Dis. 2017;216:502-503.
     PubMed     Text format    
     
     
     July 2017
158. PATEL M, Cochi S
     Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
159. ZIPURSKY S, Vandelaer J, Brooks A, Dietz V, et al
     Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     
160. PEDREIRA C, Thrush E, Jauregui B
     Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.
     J Infect Dis. 2017;216.
     PubMed     Text format     Abstract available
     
     
     May 2016
161. VIROJANAPIROM P, Lumlertdacha B, Wipattanakitchareon A, Hemachudha T, et al
     T-705 as a potential therapeutic in rabies.
     J Infect Dis. 2016.
     PubMed     Text format    
     
     
     February 2016
162. MASCITELLI L, Goldstein MR
     How regulatory T cells induction by statin drugs may impair influenza vaccine immunogenicity and effectiveness.
     J Infect Dis. 2016.
     PubMed     Text format    
     
     
     
163. TITA AT, Andrews WW
     Influenza Vaccination and Antiviral Therapy in Pregnant Women.
     J Infect Dis. 2016.
     PubMed     Text format    
     
     
     January 2016
164. VAN DAMME P
     Long-term Protection After Hepatitis B Vaccine.
     J Infect Dis. 2016.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: